Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

2000 • 16,578 citations

Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada

1999 • 1,012 citations

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1987 • 486 citations

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae

1996 • 430 citations

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1993 • 429 citations

Restricting the Selection of Antibiotic‐Resistant Mutants: A General Strategy Derived from Fluoroquinolone Studies

2001 • 391 citations

Pharmacokinetics and Pharmacodynamics of Fluoroquinolones

1999 • 281 citations

Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG and Staphylococcus aureus

1999 • 279 citations

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus

1996 • 231 citations

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

2000 • 230 citations

ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype

1996 • 226 citations

DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance

1997 • 212 citations

Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis

1976 • 207 citations

DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae

1998 • 204 citations

Development of resistance during antibiotic therapy

1987 • 179 citations

Primary Targets of Fluoroquinolones in Streptococcus pneumoniae

1999 • 166 citations

Prevalence of gyrA , gyrB , parC , and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season

2000 • 156 citations

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

1996 • 136 citations

DRUG RESISTANCE IN MYCOBACTERIA

1984 • 134 citations

Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates of Mycobacterium tuberculosis

2000 • 127 citations

Pharmacokinetics of a Once-Daily Oral Dose of Moxifloxacin (Bay 12-8039), a New Enantiomerically Pure 8-Methoxy Quinolone

1999 • 118 citations

Bacterial counts in cerebrospinal fluid of children with meningitis

1990 • 110 citations

Antimicrobial Action and Pharmacokinetics/Pharmacodynamics: The Use of AUIC to Improve Efficacy and Avoid Resistance

1999 • 104 citations

Contribution of Topoisomerase IV and DNA Gyrase Mutations in Streptococcus pneumoniae to Resistance to Novel Fluoroquinolones

1999 • 81 citations

Mechanisms of Quinolone resistance

1997 • 51 citations

Mechanisms of Quinolone Resistance

1997 • 46 citations

Pharmacokinetics of grepafloxacin

1997 • 33 citations

A review of clinical trials with fluoroquinolones with an emphasis on new agents

2000 • 23 citations

The Epidemiology of Bacterial Resistance to Antimicrobial Agents

2009 • 13 citations

The Epidemiology of Bacterial Resistance to Antimicrobial Agents

1998 • 4 citations